Vadim Gushchin, M.D., serves as Director of The Melanoma and Skin Cancer Center at Mercy as well as Director of Gastrointestinal Oncology, a division of Surgical Oncology at Mercy Medical Center in Baltimore, Maryland. Dr. Gushchin offers expertise in complex malignancies and is a skilled cancer surgeon. He is exceptionally accomplished in minimally invasive surgery – most notably in da Vinci Robotic Surgery – as well as in traditional open surgery techniques. Gastrointestinal Cancer (GI Cancers), melanoma – more commonly known as skin cancer, and thyroid cancer are among the many cancer diagnoses Dr. Gushchin treats. To determine the best treatment option for his surgical oncology patients, Dr. Gushchin carefully evaluates each patient’s risk factors, medical history, current clinical condition, surgical alternatives and post-surgical recovery options in order to fully develop a thorough, personalized care plan. Dr. Gushchin comforts and compassionately walks his patients through the treatment steps needed to care for melanoma, thyroid and parathyroid disease, peritoneal surface malignancies (abdominal tumors), and recurring tumors within the colon, rectum and liver. Dr. Gushchin is well-recognized for his experience in treating complex cancers with HIPEC (Hyperthermic Intraperitoneal Chemotherapy). Dr. Gushchin trained under the internationally renowned surgical oncologist Dr. Paul Sugarbaker to master this procedure, which involves cytoreductive surgery followed by a heated chemotherapy solution to reduce and eliminate tumors. Dr. Gushchin has participated in over 150 HIPEC surgeries and provides patients expertise in complicated HIPEC surgeries including repeat HIPEC surgeries, simultaneous liver resections at the time of HIPEC as well as other advanced surgical treatments in conjunction with HIPEC treatment. An international presenter and teacher, Dr. Gushchin has educated physicians around the world on HIPEC treatment and has organized teaching courses for the treatment of peritoneal surface malignancies (complex abdominal cancers that can be treated with HIPEC). As an extension of his knowledge and compassion, Dr. Gushchin has been instrumental in setting up treatment centers for peritoneal surface malignancies in other parts of the world including Lithuania, Siberia and Ukraine. Dr. Vadim Gushchin is one of Mercy Medical Center’s top surgical oncologists. He utilizes many of the latest innovations in technology and research to provide state-of-the-art treatment options to his patients. Dr. Gushchin brings expertise in robotic surgery, using the da Vinci robot. Patients who qualify for da Vinci robot surgery typically experience the benefits of a more precise and exacting surgery, a less invasive procedure, shorter hospital stay and faster recovery. Dr. Vadim Gushchin leads a multidisciplinary team of experts at The Melanoma and Skin Cancer Center at Mercy to treat a wide range of skin cancers. As an experienced oncology surgeon and talented cancer specialist, he uses the Isolated Limb Infusion technique to try to save an arm or leg that has been aggressively attacked by skin cancer. Isolated Limb Infusion, also known as ILI, offers patients a remarkable alternative approach to metastatic melanoma on a limb. This type of skin cancer commonly leads to amputation or a disfiguring result. Dr. Gushchin and his patients know this doesn’t always have to be the case. Isolated Limb Infusion gives Dr. Gushchin a fighting chance to save his patients’ affected arms and/or legs, reduce or shrink the cancerous tumor and avoid the need for a more radical surgery.
Professor Guzmán is a linguistic and medical anthropologist. Her present research focuses on how Latinx immigrant farmworkers in New York talk about mobility, vulnerability, and well-being. Guzmán has also conducted research on medical interaction in Chile and the United States.
Ph.D., Clinical Psychology, Florida State University; M.S., Clinical Psychology, Florida State University; B.A. Psychology & Social Behavior, Philosophy Minor, University of California, Irvine. "The block plan allows my classes to dive deep into complex issues surrounding human nature and interpersonal interaction. It also allows students to design and conduct their own short term research projects to give them a sense of what intensive research is like." Dr. Hagan's research focuses on suicide and related behaviors including non-suicidal self-injury and murder-suicide. He works with students to co-publish peer-reviewed journal articles and present at national conferences. He teaches Fundamentals of Psychology, Multicultural Psychology, Abnormal Psychology, Personality Theories, Research Methods 1, Senior Seminar, and a Seminar on suicide and related behaviors.
Juergen Hahn, Department Head of Biomedical Engineering at Rensselaer Polytechnic Institute, is a trailblazer in the use of big data methods to improve the diagnosis and treatment of Autism. His research focuses on the use of machine-learning algorithms to analyze complex biological and biomedical systems. He previously developed a physiological test for autism after discovering patterns with certain metabolites in the blood that can accurately predict diagnosis. He is applying that same approach to other areas of autism research including correlating conditions and assessing the effectiveness of possible medical treatments.
Trade, trade and transportation, Supply Chain, Supply Chain & Logistics Management, Supply Chain Management, Business, Tariff, Tariffs, Cold Chain, Lean & Process Improvement, transportation logistics, Operations Management, Production and Operations Manag
Douglas Hales is an Associate Dean and Professor of Supply Chain Management at the University of Rhode Island. His primary teaching expertise is Global Supply Chain Management and Lean Six Sigma. His research interests include Global Port Competitiveness and Applied Process Improvement. Hales has more than 20 years of operational and supply chain management experience for the U. S. Marine Corps as well as the plastics and construction industries. He can speak to the impact of U. S. imposed tariffs on Chinese goods and U. S. goods in many industries. He can discuss the delay between the tariffs and the arrival of goods being shipped to the U.S. and what consumers can expect, in terms of the timing of price hikes on goods purchased by Americans. He can discuss the “cold chain,” agricultural goods, electronics and commodities in general that ship by container vessel. Hales is a special issue co-editor for the Transportation Journal on Seaport Competition for 2018 and 2019, as well as the past Program Chair of the Northeast Decision Sciences Institute. He is also the incoming President of the Northeast Decision Sciences Institute, beginning July 1, 2019. https://web.uri.edu/business/meet/doug-hales/
I have almost 40 years of experience in the field of alcoholism research, with much of my work focusing on the molecular sites and mechanisms of alcohol action in brain. My group has extensive experience with mouse behavioral models of alcohol consumption and dependence and was involved in some of the initial studies of the neuroimmune basis of alcohol dependence. Profiling brain gene expression is key to understanding addiction, and we were among the first to study the human brain transcriptome. We have implemented microRNA profiling and next-generation sequencing to extend our studies of molecular remodeling by alcohol in human and mouse brain. We study the genetic overlap in human alcoholics and animal models of alcohol dependence and examine the neurobiological systems involved. My research encompasses the fields of genomics, behavior, systems biology, and bioinformatics. Overall, my work has combined functional, structural, behavioral, and genomic approaches to define sites of alcohol action. Currently, I am Associate Director of the Waggoner Center for Alcohol and Addiction Research at The University of Texas at Austin and previously served as Director for 20 years. I am also the Consortium Director for the Integrative Neuroscience Initiative on Alcoholism (INIA)-Neuroimmune, where our goal is to identify and test candidate drugs that may be repurposed to treat alcohol use disorders.
Dr. Josh Harris is board certified by the American Board of Orthopedic Surgery in orthopedic sports medicine. He completed his medical training and a residency in orthopedic surgery at Ohio State University College of Medicine. He also completed a fellowship in Orthopedic Surgery Sports Medicine at Rush University Medical Center. His main clinical focus is on sports injury and arthroscopic surgery for the treatment of various sports-related injuries. Harris conducts research in orthopedic sports medicine and hip preservation. Harris serves as the team physician of the Houston Ballet, and the consulting physician of Rice University Athletics.
Dr Katy Hayward is one of the leading political sociologists on the island of Ireland, and is a Reader in Sociology, and Senior Research Fellow at the Senator George J. Mitchell Institute for Global Peace, Security and Justice at Queen’s University Belfast. Dr Hayward’s research focuses on conflict/post-conflict transitions and is actively interdisciplinary, traversing fields of border studies, conflict studies, European studies, and Irish studies. This means that she is particularly well-placed to speak about the implications of Brexit for the island of Ireland, and Northern Ireland in particular, European integration, political violence, and the application of discourse analysis.
Dr. Dean Headley is an Emeritus Professor in the W. Frank Barton School of Business, at Wichita State University. He received his Ph.D. from Oklahoma State University in services marketing and statistics (1989). Dean is a native of Kansas, receiving his undergraduate business degree from Emporia State University (1970). He also has a Master of Public Health (MPH) from the University of Oklahoma (1974) and an MBA from Wichita State University (1982). Before returning for his initial graduate work, Dean worked in the area of consumer credit with Phillips Petroleum Company in Bartlesville, Oklahoma. After receiving his initial graduate degree in 1974, he worked as an HMO developer in Oklahoma, Health Systems Agency Planning Director in Wichita, and medical school Outreach Director and physician recruiter for K.U. School of Medicine in Wichita. Prior to returning to academia to earn his doctorate, Dean taught in and chaired the Department of Business at Newman University in Wichita (1982 to 1985). In 1987 he taught in the College of Health Professions at WSU and in 1988 he joined the Barton School faculty. Until his retirement in May 2018, Dean was a fulltime faculty in the Barton School at Wichita State serving for 30 years. Dr. Headley taught courses in marketing research and services marketing at WSU. You may have seen or read about Dr. Headley over the years talking about airlines. In 1991 he published the Airline Quality Rating. His research on airline quality over the past 29 years has garnered national and international attention for the University via appearances on Good Morning America, the TODAY Show, ABC 20/20, CNN and Fox network news, local television news, articles in the Wall Street Journal, New York Times, USA Today, Business Week, Forbes, Reader’s Digest, the Wichita Eagle, Wichita Business Journal, as well as other major electronic and print news outlets. His work with quality measurement is recognized by both academics and the business community as a benchmark in the measurement of service quality for the commercial airline industry.
Cheryl Healton, DrPH, is dean of the College of Global Public Health and professor of public health policy and management at New York University. A public health leader and scholar, Healton has published more than 100 peer-reviewed papers and special reports on topics including HIV/AIDS, the opioid crisis, public health education, health policy, substance abuse, and tobacco. Healton was the founding president and CEO of Legacy (now Truth Initiative), a national foundation dedicated to tobacco control created by the tobacco industry’s Master Settlement Agreement. Healton worked to further the foundation’s mission: to build a world where young people reject tobacco and anyone can quit. During her time with Legacy, Healton guided the national youth tobacco prevention counter-marketing campaign, truth®, which has been credited with reducing youth smoking prevalence to near record lows. Healton is currently focused on what lessons can be learned from the tobacco industry’s Master Settlement Agreement and applied to other public health issues, including opioids, gun violence, obesity, and global warming. https://www.nejm.org/doi/10.1056/NEJMp1802633
Hedrick received her B.S. in Biology from Salem College in Winston-Salem, North Carolina in 1984. She received her Ph.D. in Biochemistry from Wake Forest University School of Medicine in 1992, where she performed her graduate research on LDL cholesterol metabolism in the laboratory of Dr Lawrence Rudel. From 1992 to 1995, she performed her postdoctoral research on HDL metabolism in the laboratory of Dr Aldons ‘Jake’ Lusis at UCLA. From 1995 to 1999, she worked as a junior faculty member in the Division of Cardiology at UCLA, where her research focused on inflammation and endothelial function. From 2000 to 2009, Dr. Hedrick worked as a professor in the Departments of Pharmacology, Medicine, and Molecular Physiology and Biological Physics at the University of Virginia in Charlottesville. In 2009, Dr. Hedrick was awarded the Harrison Chair of Molecular Physiology and Biological Physics at the University of Virginia. Dr. Hedrick joined the faculty of LJI in the Division of Inflammation Biology in 2009. Dr. Hedrick currently serves on the NHLBI Vascular Cellular Molecular Biology Review Committee, the AAI Committee for the Status of Women, and the American Heart Association ATVB Council Leadership Committee. She is also a Fellow of the American Heart Association. Recent honors received by Dr. Hedrick include the ATVB Vascular Biology Special Recognition Award, from the American Heart Association in 2013; the Jeffrey M. Hoeg Arteriosclerosis Thrombosis and Vascular Biology Award for Basic Science and Clinical Research from the American Heart Association in 2014; and the Arteriosclerosis Thrombosis and Vascular Biology Mentor of Women Award from the American Heart Association in 2015.
Jill Heinrich is a Professor of Education. She taught high school English for eleven years, and her research interests include religious literacy and separation of church and state in American public education, masculinity studies, comparative education in Belize, and poverty and education. Heinrich teaches an off-campus course in San Pedro Town on the island of Ambergris Caye in the country of Belize. Academic History PhD in English Education, University of Iowa, 2001 MS in Secondary School Administration, University of Iowa, 2000 MS in English, Illinois State University, 1989 BA in English, Northern Illinois University, 1985
James Hendler, the Director of the Institute for Data Exploration and Applications (IDEA) at Rensselaer Polytechnic Institute is an expert in artificial intelligence and one of the originators of the “Semantic Web.” Hendler currently serves as the chair of the U.S. Technology Policy Committee for the Association of Computing Machinery (ACM) which includes subcommittees on voting and cybersecurity. He is a former member of the U.S. Air Force Science Advisory Board, the former chief scientist of the Information Systems Office at the U.S. Defense Advanced Research Projects Agency (DARPA), and a recipient of the U.S. Air Force Exceptional Civilian Service Medal. In addition to numerous other policymakers and government agencies, including the Department of Defense, Hendler has worked with the White House on the development of Data.gov, the U.S. government’s open data site, as an “Internet Web Expert.” In 2010, Hendler was named one of the 20 most innovative professors in America by Playboy magazine
Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer. Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant. EDUCATION & TRAINING MMS Harvard University, Clinical Translational Research (1997) MD Cornell University Medical College (1991) PhD Rockefeller University (1990) BS Yale University, Molecular Biophysics & Biochemistry (1984) MS Yale University, Molecular Biophysics and Biochemistry (1984) Fellowship Brigham and Women`s Hospital Fellowship Dana Farber Cancer Institute Residency Brigham and Women`s Hospital HONORS & RECOGNITION Elected to the Association of American Physicians AAP (2015) Addario Foundation Lectureship Award Bonnie Addario Foundation (2014) Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research Dana-Farber/Brigham and Women’s Cancer Center (2014) Best Doctors, New York Magazine (2014) Honorary Professor, University College London Cancer Center University College London (2012) Sikand Orator Yale University (2011) PROFESSIONAL SERVICE National Cancer Institute (2012 - Present) Thoracic Malignancy Steering Committee - National Cancer Institute
Luis Rafael Herrera-Estrella is the President's Distinguished Professor of Plant Genomics and the Director for the Center for Functional Genomics of Abiotic Stress in the Department of Plant and Soil Science at Texas Tech University's College of Agricultural Sciences & Natural Resources. Dr. Herrera-Estrella came to Texas Tech in 2018 thanks to a grant from the State of Texas Governor's University Research Initiative (GURI). He leads a team in the Center that examines how plants adapt to thrive in the presence of environmental stresses such as extreme heat and cold, drought and in the presence of brackish water sources. Herrera-Estrella is known and respected worldwide for his work in cotton genomics, having earned the distinction in 2015 as one of the 100 most influential people in biotechnology by Scientific American. He previously served as the director and full professor of the National Laboratory of Genomics for Biodiversity (LANGEBIO) in Guanajuato, Mexico, where remains a professor emeritus. His research focuses on the molecular mechanisms that allow plants to cope with a continuously changing environment. In particular, he has studied the two fundamental processes of molecular responses to light as a source of energy and a developmental signal, and nutrient availability. Herrera-Estrella was able to eventually identify DNA regulatory elements that allow plants to activate genes in response to light stimuli and the protein sequence present in many corresponding gene products that ultimately allow participation in the photosynthesis process. A holder of 15 patents, Herrera-Estrella has published more than 180 research papers and 47 book chapters and other reviews while having delivered more than 200 presentations on his work. He served as a senior international research scholar at the Howard Hughes Biomedical Institute from 2012 to 2017 and earned the Dr. Luis Federico Leloir Award in 2012 from the Argentinian Ministry of Science, Technology and Innovation. Herrera-Estrella earned his doctoral and postdoctoral degrees in genetics from the State University of Ghent, Belgium. He received his master’s degree in genetics and molecular biology from the Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, and his bachelor’s degree from Escuela Nacional de Ciencias Biológicas Instituto Politécnico Nacional.
Katie Hinde investigates the ways a mother's milk in humans and other mammals shapes infant growth, health, and neurodevelopment. Importantly, milk not only builds the infant’s body, but fuels the infant’s behavioral activity. Most recently she has begun to explore the complex evolutionary dynamics among mother, microbes, and babies. Hinde’s research impact on breastfeeding and breast milk can also translate into more personalized clinical recommendations and health optimization for mothers and their infants. She is also a leader in public outreach efforts through her "Mammals Suck... Milk!" science outreach blog. In addition, she leads the annual “March Mammal Madness”. Inspired by (but in no way affiliated with or representing) the NCAA College Basketball March Madness Championship Tournament, March Mammal Madness is an annual tournament of simulated combat competition among mammals.
Dr. Ralph Hingson is the Director of the Division of Epidemiology and Prevention Research at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Before joining NIAAA, he was Professor and Associate Dean for Research at the Boston University School of Public Health. He has authored or co-authored 170 research articles and book chapters, including studies of the effects of: (1) Raising the legal drinking age, (2) Zero tolerance laws for drivers under 21, (3) .08% legal blood alcohol limits for adult drivers, (4) comprehensive community programs to reduce alcohol problems, (5) early drinking onset on alcohol dependence, traffic crashes, unintentional injuries and physical fights after drinking, as well as 6) assessments of morbidity and mortality associated with underage drinking, drinking by U.S. college students ages 18-24, and interventions to reduce both underage and college drinking. Dr. Hingson currently serves on the World Health Organization coordinating council to implement WHO’s global strategic plan to reduce the harmful use of alcohol. In recognition of his research contributions, the Robert Wood Johnson Foundation honored Dr. Hingson in 2001 with its Innovators Combating Substance Abuse Award. In 2002, he received the Widmark Award, the highest award bestowed by the International Council on Alcohol Drugs and Traffic Safety (ICADTS). Dr. Hingson is a Past President of ICADTS. In 2003, Mothers Against Drunk Driving instituted the Ralph W. Hingson Research in Practice Annual Presidential Award, with Dr. Hingson honored as its first recipient. In 2008, the American Society of Addiction Medicine conferred the R. Brinkley Smithers Distinguished Scientist Award to Dr. Hingson. In 2014, he received the University of Pittsburgh Legacy Laureate Award. In 2016, he received ICADTS’ Borkenstein Award for “Outstanding contributions to international cooperation in alcohol and drug related traffic safety programs.” In September of 2017, Dr. Hingson will receive will receive a National Institutes of Health (NIH) 2017 Director's Award for his role as a member of the Surgeon General's Report Team for the recently-released Surgeon General’s Report on Alcohol, Drugs, and Health.
After graduating from the Yale School of Medicine, I completed an internship, residency and fellowship in Hematology-Oncology at Bellevue Hospital and NYU Medical Center. These experiences taught me that the key to success in medicine is to be patient focused and put the patient’s needs first - values that I continue to hold and practice every day. I am certified in Internal Medicine by the American Board of Internal Medicine, and by the Hematology and Oncology Boards. Since 1986, I was on the NYU faculty in medical oncology, rising to full professor before moving to the Yale Cancer Center in 2010, where I was the Associate Director for Clinical Research and head of GI Oncology until joining Rutgers Cancer Institute. My clinical expertise and research interests are dedicated to early drug development and clinical pharmacology, focused on tumors of the gastrointestinal tract. I have led numerous clinical trials and have been at the forefront of clinical research in GI Oncology and have been instrumental in the approval of eight new drugs for the treatment of colon cancer. I have authored more than 150 peer-reviewed articles on cancer therapy, new drug development and clinical trials and have presented many of these study results at national meetings. I have had two R01 funded research projects on cancer pharmacodynamics and was recently awarded a Lead Academic Participating Site Grant to support NCI sponsored clinical trials. I also have been very involved with the NCI National Clinical Trials Network (NCTN) and have chaired ten phase 2 and phase 3 studies in the NCI cooperative groups. Since 2013, I have chaired the GI Cancer Committee for SWOG (formerly, Southwestern Oncology Group), one of the four NCTN cooperative groups. Together with my SWOG and NCTN colleagues, we strive to design and conduct the studies that set standards of care for pioneering new treatments in cancer care. Other professional activities include reviewing scientific publications and grant applications in my capacity as Associate Editor for the Journal of the National Cancer Institute and Journal of GI Oncology. I also regularly review manuscripts for Journal of Clinical Oncology, Cancer, British Medical Journal and Lancet. I review grants for the NCI and the Cancer Prevention and Research Institute of Texas. I am also a Medical Director of the Chemotherapy Foundation. In my free time, I am an avid marathon runner and century cyclist. Rutgers Cancer Institute has a rich history of conducting innovative and groundbreaking cancer research, and, together with RWJBarnabas Health, we offer unparalleled knowledge, clinical care and resources for cancer patients and their families close to home. I feel privileged to work alongside the many expert cancer providers and compassionate staff. Our overall mission is to deliver outstanding cancer care and to achieve the best outcomes for our patients in New Jersey and beyond. My vision is to bring the very best in treatment via clinical trials and clinical research to the people of New Jersey and to make us a treatment destination venue for patients around the world. Positions: Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey Chief, GI Medical Oncology Director of Cancer Clinical Research, Oncology Service Line, RWJBarnabas Clinical Expertise: GI Cancers, colon cancer, pancreatic cancer, biliary cancers, neuroendocrine tumors Honors: Fullbright Scholar (Brussels, Belgium), 1985-6 Best Doctor, New York Magazine or Connecticut Magazine, 1997-2017 America’s Top Doctors, 2003-2017 Top Oncology Doctors in US, 2005-2017 Grant reviewer for NCI and Cancer and Prevention Research Institute of Texas Chair, New York Cancer Society, 2004-2006 President, International Society of Clinical Oncology, 2017-2019
James Hodge is a national expert on emergency legal preparedness, obesity laws and policies, vaccination laws and public health information privacy. His work on these and other topics has been cited in various publications including The New York Times, The Wall Street Journal, The Washington Post and additional regional newspapers, social media cites and journals. Hodge is the Peter Kiewit Foundation Professor of Law at the Sandra Day O'Connor College of Law and Director of the Center for Public Health Law and Policy at ASU. Through scholarship, teaching, and applied projects, Professor Hodge delves into multiple areas of health law, public health law, global health law, ethics, and human rights. Professor Hodge advises numerous federal, state, and local governments on public health law and policy issues and has lectured extensively on diverse topics in international locations including Sydney, Toronto and Barcelona.
Dr. Steve Hodges, a pediatric urologist who practices in Winston-Salem, NC, is a leading expert when it comes to children and issues related to toilet training, bedwetting and constipation. His own published research shows that children trained before age 2 have a much higher risk of having accidents compared to those trained later and are more likely to become habitual holders of their pee and poop, which can lead to issues with constipation. Hodges can discuss how today's today’s modern parents feel societal and financial pressure to toilet train their children before they are developmentally and physically ready. In his opinion, few children are ready to be fully toilet trained before the age of 3. He can discuss how diet affects children's bowel systems: what goes in (food) determines what comes out (poop). A diet full of highly processed foods like crackers, chicken nuggets and hotdogs without lots of vegetables, fruits and fibers often leads to constipation. Hodges can discuss how improper poop or pee posture can affect children's ability to fully eliminate: When it comes to pooping, it’s not enough to have a cute little seat in place because a “squatting” position improves childrens’ ability to fully eliminate. They need to sit on the toilet with their feet on a tall stool, leaning forward, elbows on knees. And, he can address how parents and caregivers should not ASK if their child has to go to the bathroom because they will likely say NO because they don’t want to stop whatever activity they are involved in. Instead, children should be directed to attempt to pee about every two hours and should be encouraged in a way that works for them individually. When children hold their pee at this young age, this actually leads to smaller bladder capacity which can lead to problems like bedwetting.